Novartis AG’s drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a ...

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Novartis AG offers growth potential with a balanced drug portfolio, manageable debt, and shares priced below fair value.

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

Shares have been marching higher, with the stock up 3.7% over the past month. The stock hit a new 52-week high of $121.24 in the previous session. Novartis has gained 24.4% since the start of the year ...

Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed ...

See the latest Novartis AG Registered Shares stock price (NOVN:XSWX), related news, valuation, dividends and more to help you make your investing decisions.

We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

We came across a bullish thesis on Novartis AG (NVS) on Stock Analysis Compilation’s Substack. In this article, we will ...

Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), a condition characterised by inflammation of the arteries. June 30, 2025 ...

Kirkland & Ellis lawyers withdrew from representing Novartis AG in a lawsuit against Regeneron Inc. a week after the firm was ...

See the latest Novartis AG ADR stock price (NVS:XNYS), related news, valuation, dividends and more to help you make your investing decisions.